ArticleAllergy2020
A highly sensitive bioluminescent method for measuring allergen-specific IgE in microliter samples.
Article in Allergy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- High sensitization toThe World Allergy Organization journal · 2025Article
- Viruses of parasites: A roadmap toward diagnostic and therapeutic development.PLoS neglected tropical diseases · 2025Review
- LuLIPLEX: A Fast, Highly Sensitive, and Multiplexed Method for the Detection of IgE Against Major Allergens.Allergy · 2025Article
- Article
- Biosensing strategies using recombinant luminescent proteins and their use for food and environmental analysis.Analytical and bioanalytical chemistry · 2024Review
- Widespread monoclonal IgE antibody convergence to an immunodominant, proanaphylactic Ara h 2 epitope in peanut allergy.The Journal of allergy and clinical immunology · 2024Article
- Allergy: Mechanistic insights into new methods of prevention and therapy.Science translational medicine · 2023Review
- T cell migration and effector function differences in familial adenomatous polyposis patients withFrontiers in immunology · 2023Article
- Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.Nature communications · 2021Article
- Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France: a cross-sectional study.The Lancet. Public health · 2021Article
- High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris.European journal of immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.